Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Follicular 2Polycythemia Vera 1Lymphoma 1Leukemia, Myeloid, Acute 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sunitinib 20Nivolumab 16cabozantinib 12Sorafenib 12pembrolizumab 11pazopanib 9Ipilimumab 9Interferon-alpha 9belzutifan 8Everolimus 8lenvatinib 7Bevacizumab 7aldesleukin 6Magnetic Resonance Spectroscopy 6Axitinib 6atezolizumab 5Interferon alpha-2 4temsirolimus 3Specimen Handling 3Radiosurgery 3Nephrectomy 3Interleukin-2 3tivozanib 2durvalumab 2avelumab 2Saline Solution 2G250 monoclonal antibody 2Fluorouracil 2Chemotherapy, Adjuvant 2CTLA-4 Antigen 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Renal Cell × Interferons × Clear all
NCT00311467 2012-05-16

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Central European Cooperative Oncology Group

Phase 3 Terminated
172 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡